RC
PMVP icon

Rangeley Capital’s PMV Pharmaceuticals PMVP Stock Holding History

Rangeley Capital’s Portfolio PMVP Stock Details PMVP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$133K Buy
99,240
+32,394
+48% +$41.6K 0.12% 140
2026
Q1 		$82.9K Buy
66,846
+21,346
+47% +$27.1K 0.08% 122
2025
Q4 		$56.9K Hold
45,500
– – 0.05% 114
2025
Q3 		$63.7K Buy
+45,500
New +$62.9K 0.06% 115

Other funds holding PMVP

BCM
BML Capital Management Zionsville, Indiana $176M AUM 123.21% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return
SCM
Sio Capital Management New York $604M AUM 96.57% 1-Year Est. Return
EC
Euclidean Capital New York $440M AUM 28.33% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
ACH
ArrowMark Colorado Holdings Denver, Colorado $2.4B AUM 42.85% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
EP
Eversept Partners New York $1.93B AUM 160.8% 1-Year Est. Return

Rangeley Capital's PMVP Position: Q2 2026 in Review

Rangeley Capital increased its PMV Pharmaceuticals (PMVP) stake by 48% in Q2 2026, buying an estimated $41.6K and bringing the position to 99,240 shares worth $133K. The position accounts for 0.12% of the portfolio, ranked #140.

Rangeley Capital first reported a position in PMVP in Q3 2025 and has held it in 4 quarters since. 64 funds tracked by Wall St. Rank hold PMVP as of Q2 2026.

  • Rangeley Capital held 99,240 shares of PMV Pharmaceuticals worth $133K as of Q2 2026.
  • Rangeley Capital bought 32,394 PMV Pharmaceuticals shares in Q2 2026, an estimated $41.6K.
  • PMV Pharmaceuticals made up 0.12% of Rangeley Capital's portfolio in Q2 2026, its #140 holding.
  • Rangeley Capital first reported a position in PMV Pharmaceuticals in Q3 2025 and has held it in 4 quarters since.
  • 64 funds tracked by Wall St. Rank held PMV Pharmaceuticals as of Q2 2026.

Based on Rangeley Capital's 13F filing for Q2 2026, filed 14 Aug 2026.